TY  - BOOK
AU  - Kitabata, Hironori
AU  - Loh, Joshua P
AU  - Magalhaes, Marco A
AU  - Omar, Al Fazir
AU  - Pendyala, Lakshmana K
AU  - Pichard, Augusto D
AU  - Satler, Lowell F
AU  - Suddath, William O
AU  - Torguson, Rebecca
AU  - Waksman, Ron
TI  - Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome
SN  - 1522-1946
KW  - *Acute Coronary Syndrome/su [Surgery]
KW  - *Coronary Restenosis/pc [Prevention & Control]
KW  - *Drug-Eluting Stents
KW  - *Percutaneous Coronary Intervention/mt [Methods]
KW  - *Sirolimus/aa [Analogs & Derivatives]
KW  - Acute Coronary Syndrome/di [Diagnosis]
KW  - Aged
KW  - Antineoplastic Agents
KW  - Cause of Death/td [Trends]
KW  - Coronary Restenosis/ep [Epidemiology]
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunosuppressive Agents/pd [Pharmacology]
KW  - Incidence
KW  - Male
KW  - Middle Aged
KW  - Prosthesis Design
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Sirolimus/pd [Pharmacology]
KW  - Time Factors
KW  - Treatment Outcome
KW  - Washington/ep [Epidemiology]
KW  - MedStar Heart & Vascular Institute
KW  - Comparative Study
KW  - Journal Article
N1  - Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006
N2  - BACKGROUND: There have been concerns about the long-term safety of drug-eluting stents in the setting of acute coronary syndrome; CONCLUSIONS: There was an improvement in the long-term outcome for MACE with EES when compared to earlier-generation stents, but this was comparable with the 2nd-generation E-ZES. There was no additional risk of early or late stent thrombosis in EES when compared with BMS.Copyright � 2014 Wiley Periodicals, Inc; E-ZES: HR 1.08, 95% CI 0.65-1.77, P=0.72). Stent thrombosis rates were similar for EES, E-ZES, and BMS but higher for SES throughout the 3-year follow-up (EES vs. BMS: HR 1.02, 95% CI: 0.31-3.35, P=0.973; EES vs. SES: HR 4.90, 95% CI: 1.75-13.69, P=0.002 and EES vs; E-ZES: HR 1.63, 95% CI 0.37-7.31, P=0.449); METHODS: The study cohort included 1,612 patients presenting with acute coronary syndrome who underwent BMS, SES, E-ZES, or EES implantation. End points included probable or definite stent thrombosis and major adverse cardiovascular events (MACE), defined as a composite of all-cause death, Q-wave myocardial infarction, and target lesion revascularization up to 3 years; OBJECTIVES: This study aimed to investigate the long-term safety and efficacy of everolimus-eluting stents (EES) compared with other limus-eluting stents and bare metal stents (BMS) in ACS patients; RESULTS: The overall MACE rates were significantly higher for both BMS and SES, but not E-ZES, when compared with EES (EES vs. BMS: HR 2.68, 95% CI 1.91-3.78, P <0.001; EES vs. SES: HR 1.75, 95% CI 1.24-2.47, P=0.001 and EES vs
UR  - http://dx.doi.org/10.1002/ccd.25469
ER  -